|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Pfizer |
|---|---|
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00054886 |
Purpose
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Kidney Neoplasms |
Drug: SU-011,248 |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma |
| Estimated Enrollment: | 63 |
| Study Start Date: | January 2003 |
| Study Completion Date: | August 2004 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Pfizer Investigational Site | |
| Los Angeles, California, United States, 90095 | |
| Pfizer Investigational Site | |
| Mission Hills, California, United States, 91345 | |
| Pfizer Investigational Site | |
| Monterey Park, California, United States, 91754 | |
| Pfizer Investigational Site | |
| Northridge, California, United States, 91328 | |
| Pfizer Investigational Site | |
| San Francisco, California, United States, 94115 | |
| Pfizer Investigational Site | |
| San Francisco, California, United States, 94121 | |
| United States, Massachusetts | |
| Pfizer Investigational Site | |
| Boston, Massachusetts, United States, 02114 | |
| Pfizer Investigational Site | |
| Boston, Massachusetts, United States, 02115 | |
| United States, Michigan | |
| Pfizer Investigational Site | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, Nevada | |
| Pfizer Investigational Site | |
| Henderson, Nevada, United States, 89052 | |
| Pfizer Investigational Site | |
| Las Vegas, Nevada, United States, 89109 | |
| Pfizer Investigational Site | |
| Las Vegas, Nevada, United States, 89128 | |
| United States, New York | |
| Pfizer Investigational Site | |
| New York, New York, United States, 10021 | |
| United States, Pennsylvania | |
| Pfizer Investigational Site | |
| Philadelphia, Pennsylvania, United States, 19111 | |
| United States, Wisconsin | |
| Pfizer Investigational Site | |
| Madison, Wisconsin, United States, 53792 | |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
| Study ID Numbers: | RTKC-0511-014 |
| Study First Received: | February 12, 2003 |
| Last Updated: | May 4, 2007 |
| ClinicalTrials.gov Identifier: | NCT00054886 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Neoplasms Neoplasms by Site Urologic Diseases Kidney Neoplasms |
Urogenital Neoplasms Kidney Diseases Urologic Neoplasms |